XpresSpa Group

XWELL, Inc. provides global travel health and wellness services. It operates through the following segments: XpresSpa, XpresTest, Treat, and Corporate and Other. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. The Treat segment consists of access to integrated care which can seamlessly fit into a post-pandemic world and is designed to deliver on-demand access to integrated healthcare through technology and personalized services, positioned for a traveler to access health care, records and real-time information all in one place. The company was founded by Jonathan Medved and David Goldfarb on January 9, 2006 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

XWELL, Inc. provides global travel health and wellness services. It operates through the following segments: XpresSpa, XpresTest, Naples Wax Center, Treat, and Corporate & Other. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. The Naples Wax Center segment is focused on the products and service offerings from face and body waxing to a range of skincare and cosmetic products. The Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers. The company was founded by Jonathan Medved and David Goldfarb on January 9, 2006 and is headquartered in New York, NY.

XpresSpa's share price remains dangerously low at around 75 cents, but the revival of the spa business offers hope.

XpresSpa Pivots Back From Covid Testing With A More Balanced Retail Vision

New suite of curated products for women are clean, sustainable and primarily sourced from women-owned companies New suite of curated products for women are clean, sustainable and primarily sourced from women-owned companies

XpresSpa Group Expands Retail Products for Women, Underscoring Company's Commitment to Support Women's Health and Wellness

XpresSpa Group, Inc. (NASDAQ:XSPA ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Omar Haynes - Interim CFO Scott Milford - CEO Joseph Calabrese - IR Conference Call Participants Operator Good day, and welcome to XpresSpa Group's Second Quarter 2022 Results Conference Call. [Operator Instructions] Please note this event is being recorded.

XpresSpa Group, Inc. (XSPA) CEO Scott Milford on Q2 2022 Results - Earnings Call Transcript

XpresSpa Group, Inc. (XSPA) delivered earnings and revenue surprises of 20% and 1.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

XpresSpa Group, Inc. (XSPA) Reports Q2 Loss, Tops Revenue Estimates

XpresCheck, through its Partnership with Ginkgo Bioworks, Awarded  New CDC Biosurveillance Contract Valued Up To $61 Million

XpresSpa Group Reports Second Quarter 2022 Results

Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurity Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurity

Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC's Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports

Resurgence of Travel Sees Surge in Demand of Airport Self-care Solutions and Amenities for Passengers Resurgence of Travel Sees Surge in Demand of Airport Self-care Solutions and Amenities for Passengers

XpresSpa Group Announces the Re-Opening of XpresSpa™ Location at John F. Kennedy International Airport's Terminal 4

Webcast and Conference Call Scheduled for 4:30 PM ET Webcast and Conference Call Scheduled for 4:30 PM ET

XpresSpa Group to Announce Second Quarter 2022 Financial Results on Monday, August 15

NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA), a travel health and wellness company, announced it is expanding its operations outside the United States with the opening of XpresSpa locations at Istanbul Airport in Turkey beginning September 2022. This is the first of five new XpresSpa locations expected to open at Istanbul Airport.

XpresSpa Group Announces Plan for Expansion Internationally

Omar Haynes Named Interim Chief Financial Officer Omar Haynes Named Interim Chief Financial Officer

XpresSpa Group Announces the Separation of Service of Chief Financial Officer James Berry

NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA), a travel health and wellness company, today announced that its Board of Directors has authorized a 10 million share increase to its existing stock repurchase program and to extend it through September 15, 2023.

XpresSpa Group, Inc. Announces 10 Million Share Increase in Stock Repurchase Program

XpresSpa Group, Inc. (XSPA) delivered earnings and revenue surprises of 33.33% and 23.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

XpresSpa Group, Inc. (XSPA) Reports Q1 Loss, Tops Revenue Estimates

XpresSpa Group, Inc. (NASDAQ:XSPA ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants James Berry - Chief Financial Officer Scott Milford - Chief Executive Officer Raphael Gross - Investor Relations Conference Call Participants Operator Greetings, and welcome to XpresSpa Group's First Quarter 2022 Earnings Conference Call. During the presentation, all participants will be in listen-only mode.

XpresSpa Group, Inc.'s (XSPA) CEO Scott Milford on Q1 2022 Results - Earnings Call Transcript

Articulates Four Strategic Imperatives to Accelerate Company Evolution as a Leading Health and Wellness Provider for ‘People on the Go'

XpresSpa Group Reports First Quarter 2022 Results

XpresSpa Group to Announce First Quarter 2022 Financial Results on May 16

Checkpoint Therapeutics

Clarus Therapeutics Holdings

Time to sell these penny stocks? The post Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?

Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?

The one-stop travel, health, and wellness provider is transforming care access through a suite of integrated services for people on the go The one-stop travel, health, and wellness provider is transforming care access through a suite of integrated services for people on the go

XpresSpa Group's Travel Health and Wellness Brand Treat™ Launches at Phoenix Sky Harbor International Airport

Located pre-security in the South Walk area of the Main Terminal Located pre-security in the South Walk area of the Main Terminal

XpresCheck® Opens COVID-19 Testing Facility at Orlando International Airport

This summer, the company will expand its international presence and offer select travel retail and wellness services at New Istanbul Airport This summer, the company will expand its international presence and offer select travel retail and wellness services at New Istanbul Airport

XpresSpa Group Announces the Addition of Five New XpresSpa Locations in Istanbul

Ginkgo Bioworks Holdings

The joint, voluntary COVID-19 testing program successfully identified Omicron sublineages BA.2 and BA.3 weeks before the next reported U.S. detections BOSTON , March 23, 2022 /PRNewswire/ -- Concentric by Ginkgo, the public health and biosecurity initiative of Ginkgo Bioworks (NYSE: DNA), today released new findings from its joint SARS-CoV-2 monitoring program with the Centers for Disease Control and Prevention (CDC) and XpresCheck®, a subsidiary of XpresSpa Group, Inc (Nasdaq: XSPA). The findings, published in a preprint yesterday on medRxiv , outline how this voluntary Traveler-Based SARS-CoV-2 Genomic Surveillance program operates as an early warning system and closes a gap in national public health security.

CDC, Concentric by Ginkgo and XpresCheck® Publish Results of CDC COVID-19 Air Travel Biosecurity Program at International Airports

XpresSpa Group, Inc. (XSPA) CEO Scott Milford on Q4 2021 Results - Earnings Call Transcript

Strongest Financial Results in Company History Marks End to Banner Year

XpresSpa Group Reports Record Full Year 2021 Results

XpresSpa Group to Announce Fourth Quarter and Full Year 2021 Financial Results on March 15

XpresSpa Group Inc (NASDAQ: XSPA) has  extended its initial $2 million airport-based biosurveillance program with the Centers for Disease Control and Prevention (CDC) through its subsidiary XpresCheck. The extension brings the total contract to $5.6 million.

XpresSpa Extends Partnership With CDC For Biosurveillance At US Airports

SARS-CoV-2 Variant Identification Program Expands Beyond Initial Pilot; Now Totals $5.6 Million SARS-CoV-2 Variant Identification Program Expands Beyond Initial Pilot; Now Totals $5.6 Million

XpresSpa Group Extends Collaboration with Centers for Disease Control and Prevention (CDC) to Conduct Ongoing COVID-19 Biosurveillance at U.S. Airports

News for XpresSpa Group Stock (XSPA)